Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo

Journal of Immunology

Volumn 161, Issue 5, 1998, Pages 2187-2194

  Prévost Blondel, Armelle ^a   Zimmermann, Christine ^a   Stemmer, Christine ^a   Kulmburg, Peter ^b   Rosenthal, Felicia M ^b   Pircher, Hanspeter ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS GLYCOPROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GLYCOPROTEINS; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

EID: 0032169195     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rivoltini, L., K. C. Barracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class 1 allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
2. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J. J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, and P. L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 18:89.
3. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
4. Torre-Amione, G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A high immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87:1468.
5. Ranges, G. E., I. S. Figari, T. Espevik, and M. A. Palladino. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166:991.
6. Onrust, S. V., P. M. Harti, S. D. Rosen, and D. Hanahan. 1996. Modulation of L-selectin ligand expression during an immune response accompanying tumori-genesis in transgenic mice. J. Clin. Invest. 97:54.
7. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
8. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
9. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66:470.
10. Van den Eynde, B. J., and P. Van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684.
11. Yron, I., T. A. Wood, J. P. J. Spiess, and S. A. Rosenberg. 1980. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngenic solid tumors. J. Immunol. 125:238.
12. Mesler Muul, L., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989.
13. Itoh, K., C. D. Platsoucas, and C. M. Balch. 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastic melanomas: activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168:1419.
14. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
15. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D. E. White. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319:1676.
16. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
17. Pircher, H., K. Burki, R. Lang, H. Hengartner, and R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559.
18. Kyburz, D., P. Aichele, D. E. Speiser, H. Hengartner, R. Zinkernagel, and H. Pircher. 1993. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1956.
19. Ohashi, P. S., R. M. Zinkernagel, I. Leuscher, H. Hengartner, and H. Pircher. 1993. Enhanced positive selection of a transgenic TCR by a restriction element that does not permit negative selection. Int. Immunol. 5:131.
20. Fidler, I. J. 1973. Selection of successive tumor lines for metastasis. Nature 242:148.
21. Kulmburg, P., H. Veelken, C. Schmoor, F. M. Rosenthal, A. Mackensen, A. Lindemann, and R. Mertelsmann. 1997. NTS influence on transgene expression from mono- and bicistronic plasmid vectors after lipofection in a human fibroblast cell line. J. Mol. Med. 75:223.
22. Battegay, M., S. Cooper, A. Althage, J. Baenziger, H. Hengartner, R. Zinkernagel, and H. Pircher. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24 or 96 well plates. J. Virol. Methods 33:191.
23. Zinkernagel, R. M., T. P. Leist, H. Hengartner, and A. Althage. 1985. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 162:2125.
24. Wick, M., P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progressively in human hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229.
25. Mueller, D. L., M. K. Jenkins, and R. H. Schwartz. 1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:445.
26. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
27. + T cells by B7-transfected melanoma cells. Science 259:368.
28. Huang, A. Y. C., P. Golumbeck, M. Ahmadzadeh, E. Jaffee, D. M. Pardoll, and H. I. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
29. Kündig, T. M., M. F. Bachmann, C. DiPaolo, J. J. L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343.
30. Kündig, T. M., A. Shahinian, K. Kawai, H.-W. Mittrucker, E. Sebzda, M. F. Bachmann, T. W. Mak, and P. S Ohashi. 1996. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5:41.
31. Lucas, P. J., I. Negishi, K.-I. Nakayama, L. E. Fields, and D. Y. Loh. 1995. Naive CD28-dencient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154:5757.
32. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P. G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340.
33. +) T cells established from mutine tumor-infiltrating lymphocytes. J. Immunol. 158:4846.
34. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E. Chang. 1997. Type 1 versus type 2 cytokine release by Vb T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159:664.
35. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
36. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 24:1966.
37. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.
38. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. El-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
39. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
40. Kundig, T. M., M. F. Bachmann, S. Oehen, U. W. Hoffmann, J. J. L. Simard, C. P. Kalberer, H. Pircher, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1996. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. USA 93:9716.
41. + memory T cells in virus-infected hosts. J. Exp. Med. 183:1367.
42. Selin, L. K., and R. M. Welsh. 1997. Cytolytically active memory CTL present in lymphocytic choriomeningitis virus-immune mice after clearance of virus infection. J. Immunol. 158:5366.